Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
Yahoo/Zacks.com
Sat, 09/2/17 - 11:11 am
Tags:
Parkinson's Disease, Novartis, Teva Pharmaceutial, UCB Pharma, MEDI1341, AstraZeneca, Takeda, PRX002, Prothena, Roche, Acorda, Inbrija, Adamas Pharmaceuticals, Gocovri
Novartis CEO: Here's How We Handled A Milestone In Pediatric Cancer
Forbes
Fri, 09/1/17 - 04:08 pm
Tags:
Novartis, Pharma CEOs, Joe Jimenez, pediatrics, pediatric cancer
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
BioPharma Dive
Fri, 09/1/17 - 11:24 am
Tags:
Novartis, CAR-T, Kymriah, FDA, drug manufacturing
Profit on $475,000 Novartis cancer drug could be a while coming
Yahoo/Reuters
Fri, 09/1/17 - 11:15 am
Tags:
Novartis, CAR-T, Kymriah
Why bluebird bio Inc Continued Its March Higher Again Today
Motley Fool
Thu, 08/31/17 - 10:13 pm
Tags:
Bluebird Bio, bb2121, CAR-T, Novartis, Kymriah, Gilead Sciences, Kite Pharma
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences
Motley Fool
Thu, 08/31/17 - 10:11 pm
Tags:
Novartis, CAR-T, Kymriah, Gilead Sciences, Kite Pharma, M&A
Novartis, UCSF researchers urge FDA to clean up its messy adverse events database
Endpoints
Thu, 08/31/17 - 10:50 am
Tags:
Novartis, FDA, adverse events
A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates
Forbes
Thu, 08/31/17 - 09:17 am
Tags:
CAR-T, precision medicine, drug pricing, Novartis, Kymriah
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Forbes
Wed, 08/30/17 - 11:53 pm
Tags:
Novartis, CAR-T, drug pricing, FDA, acute lymphoblastic leukemia, Kymriah, Joe Jimenez
Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000
Xconomy
Wed, 08/30/17 - 11:48 pm
Tags:
Novartis, FDA, CAR-T, drug pricing, Kymriah, acute lymphoblastic leukemia
ESC: Novartis faces an uphill battle turning niche drug Ilaris into a cardio blockbuster
Fierce Pharma
Tue, 08/29/17 - 11:05 am
Tags:
Novartis, Ilaris
Novartis shares slip after mixed heart drug data
Yahoo/Reuters
Mon, 08/28/17 - 09:33 am
Tags:
Novartis, canakinumab, Ilaris, cardiovascular disease
Best Pharma Stocks Based on R&D Spending
Motley Fool
Mon, 08/28/17 - 09:27 am
Tags:
R&D, pharma stocks, Roche, Novartis, Pfizer, JNJ, Merck
Novartis Drug May Be A New Way To Prevent Heart Attacks -- And Perhaps Cancer, Too
Forbes
Sun, 08/27/17 - 05:52 pm
Tags:
Novartis, inflammation, heart attacks, Illaris
Pharma Stocks That Could Move On New Data
Barron's
Sat, 08/26/17 - 07:36 pm
Tags:
pharma stocks, AbbVie, Bayer, Novartis, Bristol-Myers Squibb, Eli Lilly, European Society of Cardiology
Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Endpoints
Fri, 08/25/17 - 09:53 am
Tags:
Novartis, Xoma, M&A, gevokizumab, cardiovascular disease
Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England?
Fierce Pharma
Thu, 08/24/17 - 05:11 pm
Tags:
Novartis, Kisqali, Pfizer, Ibrance, reimbursement, breast cancer
AmerisourceBergen-owned specialty pharmacy to pay $13.4M to settle kickback allegations
Bizjournals.com
Thu, 08/24/17 - 11:28 am
Tags:
AmerisourceBergen, kickbacks, False Claims Act, Novartis, Exjade
Meet Bertrand Bodson, Novartis’ new global digital strategy maestro for all things Big Pharma
Endpoints
Thu, 08/24/17 - 10:03 am
Tags:
Novartis, digital pharma, Big Pharma
Profit finally in sight for gene therapy specialist Oxford Bio
Yahoo/Reuters
Wed, 08/23/17 - 10:07 pm
Tags:
gene therapy, Oxford BioMedica, CTL019, Novartis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.